Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

Please enter a short title for this project (maximum 70 characters)
The 'Big Baby Trial'

1. Is your project research?

(●) Yes ( ) No

2. Select one category from the list below:

( ) Clinical trial of an investigational medicinal product

( ) Clinical investigation or other study of a medical device

( ) Combined trial of an investigational medicinal product and an investigational medical device

(●) Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice

( ) Basic science study involving procedures with human participants

( ) Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology

( ) Study involving qualitative methods only

( ) Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)

( ) Study limited to working with data (specific project only)

( ) Research tissue bank

( ) Research database

If your work does not fit any of these categories, select the option below:

( ) Other study

2a. Will the study involve the use of any medical device without a CE Mark, or a CE marked device which has been modified or will be used outside its intended purposes?

( ) Yes (●) No

2b. Please answer the following question(s):

a) Does the study involve the use of any ionising radiation? ( ) Yes (●) No

b) Will you be taking new human tissue samples (or other human biological samples)? ( ) Yes (●) No

c) Will you be using existing human tissue samples (or other human biological samples)? ( ) Yes (●) No

3. In which countries of the UK will the research sites be located?*(Tick all that apply)*

- [x] England
- [x] Scotland
- [x] Wales
- [x] Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:

- (•) England
- ( ) Scotland
- ( ) Wales
- ( ) Northern Ireland
- ( ) This study does not involve the NHS

4. Which applications do you require?

- [x] IRAS Form
- [ ] Confidentiality Advisory Group (CAG)
- [ ] Her Majesty's Prison and Probation Service (HMPPS)

5. Will any research sites in this study be NHS organisations?

(•) Yes ( ) No

5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or Medtech and In Vitro Diagnostic Cooperative in all study sites?

Please see information button for further details.

( ) Yes (•) No

Please see information button for further details.

5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?

Please see information button for further details.

(•) Yes ( ) No

The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".

If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.

6. Do you plan to include any participants who are children?

◉ Yes ○ No

7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?

○ Yes ◉ No

Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.

8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?

○ Yes ◉ No

9. Is the study or any part of it being undertaken as an educational project?

○ Yes ◉ No

10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?

○ Yes ◉ No

11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?

○ Yes ◉ No

NOTICE OF SUBSTANTIAL AMENDMENT

Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of investigational medicinal products (CTIMPs).
The form should be completed by the Chief Investigator using language comprehensible to a lay person.

Details of Chief Investigator:

	Title	Forename/Initials	Surname
	Professor	Siobhan	Quenby
Work Address	Clifford Bridge Road, Coventry		
PostCode	CV2 2DX		
Email	s.quenby@warwick.ac.uk		
Telephone	07873416716		
Fax			

For guidance on this section of the form refer to the guidance

Full title of study:	Induction of labour for predicted macrosomia
Lead sponsor:	University Hospitals Coventry and Warwickshire NHS Trust
Name of REC:	South West-Exeter Research Ethics Committee
REC reference number:	18/SW/0039

International Standard Randomised Controlled Trial Number (ISRCTN):	ISRCTN18229892
ClinicalTrials.gov Identifier (NCT number):	

Additional reference number(s):

Ref.Number Description	Reference Number

Name of lead R&D office:	University Hospitals Coventry & Warwickshire
Date study commenced:	01 January 2018
Protocol reference (if applicable), current version and date:	V5.0 19 December 2018
Amendment number and date:	AM06 28 May 2019

Type of amendment

(a) Amendment to information previously given in IRAS

◉ Yes ○ No

If yes, please refer to relevant sections of IRAS in the "summary of changes" below.

A47 - Sonographers are integral to the identification and referral of potential trial participants. The sonographers do not explain the trial to prospective participants or recruit women into the trial, but are helpful in identification only. With this in mind, we would like to help establish and build good working relationships between sonographers and research midwives by providing gift vouchers as a 'thank you' that the research midwives can gift to the sonographers for referring potentially eligible participants.

(b) Amendment to the protocol

◉ Yes ○ No

If yes, please submit either the revised protocol with a new version number and date, highlighting changes in bold, or a document listing the changes and giving both the previous and revised text.

(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting documentation for the study

◉ Yes ○ No

If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold.

Is this a modified version of an amendment previously notified and not approved?

○ Yes ◉ No

Summary of changes

Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study.
If this is a modified amendment, please explain how the modifications address the concerns raised previously by the ethics committee.
If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained.

Protocol
1.3 – Added in the rational for induction at 38+0 to 38+4. This was previously not present, but was requested by the Data Monitoring Committee
2.8.2 – Clarification that if the woman is otherwise eligible for the trial, and was given the Participant Information Sheet prior to booking a planned caesarean section or induction (for suspected LGA baby), she is eligible to be in the cohort group. To add clarity to the recruitment process following queries from site.
2.3, 2.9, 2.9.2.5 – Clarification of the objective for collecting data in the Cohort groups. This was previously not present in enough detail. Clarification that for women in the parallel cohort study who are planning to deliver by caesarean section the same data (neonatal, infant, and maternal outcomes including the two and six month follow-up questionnaires) will be collected as those who agreed to be randomised. Additionally, for women in the cohort group not planning a caesarean section we will now collect a reduced dataset, which has been defined, to reduce the workload at site as recommended by the Trial Steering Committee.
2.9 – Clarification that at baseline, prior to randomisation we will collect routine demographic data; age, ethnicity, parity, height and smoking status. This was not previously specified in the protocol, but was present in the Detailed Project Description.
2.9.2.3 – Inclusion of adjudication committee for assessment of possible birth injuries at 2 months. This was not previously specified in the protocol, but was present in the Detailed Project Description.
2.9.2.3- We have defined the Follow Up data collection process, including the process for collecting questionnaires from women who do not speak English. This was not previously documented in the protocol.
3.1 – We would like consultant midwives to provide 'obstetric confirmation' in order to confirm that the woman is medically suitable to be entered into the trial.

4 – Following feedback from the data Monitoring Committee and the Trial Steering Committee, we have redefined the Serious Adverse Events that need reporting, clarified which Adverse Events are already collected in the CRF as outcomes, clarified that SAEs need reporting within 24 hours of site becoming aware of the event and defined SAEs that are expected.

Trifold information leaflet
The wording has been amended to make it consistent with V5.0 of the patient information sheet. The information about taking part has been clarified. It has been made clearer for the participant that in the first instance they should contact the research midwife about the trial rather than their own obstetrician or the CTU.

We would like to gain approval for the use of the following new documents:

Big Baby Questionnaire Cover Letter

Big Baby Poster 1

Big Baby Clinician Poster

Any other relevant information

Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is sought.

List of enclosed documents

Document	*Version*	*Date*
Big Baby Protocol-tracked	v6.0	16/05/2019
Big Baby Trifold-information leaflet- tracked	v2.0	13/05/2019
Big Baby Clinician Poster	v1.0	15/05/2019
Big Baby Poster 1	v1.0	15/05/2019
Big Baby Questionnaire cover letter	v1.0	13/05/2019
Big Baby Follow-up questionnaire messages	v1.0	16/05/2019
Covering letter		

Declaration by Chief Investigator

1. *I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.*
2. *I consider that it would be reasonable for the proposed amendment to be implemented.*

This section was signed electronically by Professor Siobhan Quenby on 28/05/2019 13:29.

Job Title/Post:	Prof of Obstetrics
Organisation:	University of Warwick
Email:	s.quenby@warwick.ac.uk

Declaration by the sponsor's representative

I confirm the sponsor's support for this substantial amendment.

This section was signed electronically by Ceri Jones on 28/05/2019 10:43.

Job Title/Post:	Head of R&D
Organisation:	UHCW NHS Trust
Email:	ceri.jones@uhcw.nhs.uk